FDA tells Allergan (AGN -1%) it needs more info about Botox before approving it to treat...

|About: Allergan plc (AGN)|By:, SA News Editor

FDA tells Allergan (AGN -1%) it needs more info about Botox before approving it to treat post-stroke spasticity of the upper limbs, but doesn't ask for new trials. Analysts say the news - which could delay approval for 8-9 months - is disappointing, but doesn't hamper the long-term outlook.